This HTML5 document contains 62 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
yago-reshttp://yago-knowledge.org/resource/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
n4https://global.dbpedia.org/id/
n18http://dbpedia.org/resource/List_of_drugs:
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
n19http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#
freebasehttp://rdf.freebase.com/ns/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
dbphttp://dbpedia.org/property/
dbchttp://dbpedia.org/resource/Category:
provhttp://www.w3.org/ns/prov#
xsdhhttp://www.w3.org/2001/XMLSchema#
goldhttp://purl.org/linguistics/gold/
wikidatahttp://www.wikidata.org/entity/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:Arnon_Rosenthal
dbo:wikiPageWikiLink
dbr:Ponezumab
Subject Item
dbr:Ponezumab
rdf:type
dbo:ChemicalSubstance dbo:MonoclonalAntibody dbo:Drug owl:Thing wikidata:Q8386 n19:ChemicalObject
rdfs:label
Ponezumab
rdfs:comment
Ponezumab is a humanized monoclonal antibody designed for the treatment of Alzheimer's disease. Ponezumab was developed by Pfizer Inc.In November 2011 Pfizer halted the development of ponezumab after finishing a phase 2 trial.
dcterms:subject
dbc:Treatment_of_Alzheimer's_disease dbc:Pfizer_brands dbc:Experimental_drugs
dbo:wikiPageID
33024111
dbo:wikiPageRevisionID
1047293747
dbo:wikiPageWikiLink
dbr:Beta-amyloid dbr:Alzheimer's_disease dbr:Pfizer dbc:Experimental_drugs dbc:Treatment_of_Alzheimer's_disease dbc:Pfizer_brands
owl:sameAs
n4:4tjBQ freebase:m.0h53_1n yago-res:Ponezumab wikidata:Q7227765
dbp:wikiPageUsesTemplate
dbt:Monoclonals_for_bone,_musculoskeletal,_circulatory,_and_neurologic_systems dbt:Monoclonal-antibody-stub dbt:Fdacite dbt:Nervous-system-drug-stub dbt:Cascite dbt:Drugbox dbt:Chemspidercite dbt:Reflist dbt:Drugbankcite
dbp:atcPrefix
none
dbp:c
6552
dbp:casNumber
1178862
dbp:chemspiderid
none
dbp:h
10158
dbp:kegg
D09952
dbp:n
1730
dbp:o
2090
dbp:s
52
dbp:source
zu/o
dbp:target
dbr:Beta-amyloid
dbp:type
mab
dbp:unii
1
dbp:verifiedfields
changed
dbp:verifiedrevid
464210715
dbp:watchedfields
changed
dbo:abstract
Ponezumab is a humanized monoclonal antibody designed for the treatment of Alzheimer's disease. Ponezumab was developed by Pfizer Inc.In November 2011 Pfizer halted the development of ponezumab after finishing a phase 2 trial.
dbp:mabType
mab
gold:hypernym
dbr:Antibody
prov:wasDerivedFrom
wikipedia-en:Ponezumab?oldid=1047293747&ns=0
dbo:wikiPageLength
2598
dbo:casNumber
1178862-65-1
dbo:fdaUniiCode
1TG15H1XE9
dbo:kegg
D09952
foaf:isPrimaryTopicOf
wikipedia-en:Ponezumab
Subject Item
dbr:List_of_therapeutic_monoclonal_antibodies
dbo:wikiPageWikiLink
dbr:Ponezumab
Subject Item
dbr:Rinat_Neuroscience_Corporation
dbo:wikiPageWikiLink
dbr:Ponezumab
Subject Item
n18:_Pj–Pra
dbo:wikiPageWikiLink
dbr:Ponezumab
Subject Item
wikipedia-en:Ponezumab
foaf:primaryTopic
dbr:Ponezumab